gsk201405076k.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending May 2014
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 

GlaxoSmithKline plc - Result of AGM

GlaxoSmithKline plc (GSK) announces that at its Annual General Meeting (AGM) today, all resolutions were passed by shareholders.

GlaxoSmithKline AGM Poll Results

The following table shows the votes cast for each resolution:
 
Resolution
Total votes for*
%
Total votes against
%
Total votes cast
Votes withheld**
1
Adoption of Directors' Report and Financial Statements
3,547,982,735
98.85
41,278,849
1.15
3,589,261,584
10,176,355
2
Approval of the Remuneration Report
3,377,865,669
98.52
50,641,769
1.48
3,428,507,438
170,934,805
3
Approval of the Directors' Remuneration Policy
3,408,815,630
97.42
90,250,943
2.58
3,499,066,573
100,375,670
4
Re-election of Sir Christopher Gent
3,439,528,694
95.90
147,149,979
4.10
3,586,678,673
12,768,786
5
Re-election of Sir Andrew Witty
3,578,767,397
99.72
10,010,466
0.28
3,588,777,863
10,669,596
6
Re-election of Professor Sir Roy Anderson
3,579,231,977
99.74
9,439,851
0.26
3,588,671,828
10,774,711
7
Re-election of Dr Stephanie Burns
3,576,112,095
99.65
12,610,100
0.35
3,588,722,195
10,724,344
8
Re-election of Stacey Cartwright
3,568,976,499
99.45
19,694,382
0.55
3,588,670,881
10,775,379
9
Re-election of Simon Dingemans
3,542,608,802
98.72
45,996,505
1.28
3,588,605,307
10,841,886
10
Re-election of Lynn Elsenhans
3,585,307,313
99.91
3,293,782
0.09
3,588,601,095
10,845,444
11
Re-election of Judy Lewent
3,549,394,841
98.91
39,226,163
1.09
3,588,621,004
10,825,535
12
Re-election of Sir Deryck Maughan
3,561,179,474
99.24
27,416,814
0.76
3,588,596,288
10,850,250
13
Re-election of Dr Daniel Podolsky
3,579,219,741
99.74
9,358,778
0.26
3,588,578,519
10,868,020
14
Re-election of Dr Moncef Slaoui
3,574,560,380
99.61
14,055,744
0.39
3,588,616,124
10,831,335
15
Re-election of Tom de Swaan
3,525,650,902
98.30
61,002,251
1.70
3,586,653,153
12,793,386
16
Re-election of Jing Ulrich
3,585,201,858
99.91
3,322,988
0.09
3,588,524,846
10,921,427
17
Re-election of Hans Wijers
3,280,229,504
91.57
301,809,653
8.43
3,582,039,157
17,407,382
18
Re-appointment of auditors
3,503,022,193
98.93
37,982,934
1.07
3,541,005,127
58,441,412
19
Remuneration of auditors
3,520,845,776
99.32
23,984,857
0.68
3,544,830,633
54,615,906
20
Authority for the company to make donations to political organisations and incur political expenditure
3,498,414,617
97.67
83,465,800
2.33
3,581,880,417
17,567,042
21
Authority to allot shares
3,478,465,018
97.01
107,214,629
2.99
3,585,679,647
13,766,892
22
Disapplication of pre-emption rights***
3,497,328,599
97.60
85,983,069
2.40
3,583,311,668
16,135,585
23
Authority for the company to purchase its own shares***
3,578,605,038
99.73
9,538,332
0.27
3,588,143,370
11,302,119
24
Exemption from statement of senior statutory auditor's name
3,568,553,870
99.57
15,538,722
0.43
3,584,092,592
15,354,867
25
Authorise reduced notice of a general meeting other than an AGM***
3,204,747,061
89.37
381,205,594
10.63
3,585,952,655
13,494,803

 
Sir Robert Wilson did not stand for re-election as a Director, and has stepped down from the Board with effect from the conclusion of the AGM.
 

 
The following table provides further relevant information:
 
 
GlaxoSmithKline's Fourteenth AGM
(2014)
GlaxoSmithKline's Thirteenth AGM
(2013)
Issued share capital
(excluding Treasury Shares)
4,861,007,167
4,922,724,518
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)
74.05%
76.50%
Total shareholder population
140,792
144,196
Total number of proxies lodged
8,333
8,931
% of shareholders who lodged proxies
5.92%
6.19%
Number of shareholders, corporate representatives and proxies who attended the AGM
429
442

In accordance with Listing Rule 9.6.2, copies of the resolutions that do not constitute ordinary business at an annual general meeting will be submitted to the UK Listing Authority and will in due course be available for inspection at www.morningstar.co.uk/uk/NSM and on the company's website at http://www.gsk.com/investors/shareholder-information/annual-general-meeting.html

Notes:
*           Includes discretionary votes.
**        A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.
***      Indicates Special Resolutions requiring a 75% majority.
 


V A Whyte
Company Secretary
7 May 2014
 
GSK enquiries:
      
UK Media enquiries:
David Mawdsley
+44 (0) 20 8047 5502
(London)
 
Simon Steel
+44 (0) 20 8047 5502
(London)
 
David Daley
+44 (0) 20 8047 5502
(London)
 
Catherine Hartley
+44 (0) 20 8047 5502
(London)
 
Sarah Spencer
+44 (0) 20 8047 5502
(London)
       
US Media enquiries:
Stephen Rea
+1 215 751 4394
(Philadelphia)
 
Melinda Stubbee
+1 919 483 2510
(North Carolina)
 
Mary Anne Rhyne
+1 919 483 0492
(North Carolina)
 
Emily Beamer
+1 215 751 6622
(Philadelphia)
 
Jennifer Armstrong
+1 215 751 5664
(Philadelphia)
       
Analyst/Investor enquiries:
Ziba Shamsi
+44 (0) 20 8047 5543
(London)
 
Kirsty Collins (SRI & CG)
+44 (0) 20 8047 5534
(London)
 
Tom Curry
+ 1 215 751 5419
(Philadelphia)
 
Gary Davies
+44 (0) 20 8047 5503
(London)
 
James Dodwell
+44 (0) 20 8047 2406
(London)
 
Jeff McLaughlin
+1 215 751 7002
(Philadelphia)
 
Lucy Singah
+44 (0) 20 8047 2248
(London)

 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: May 07, 2014 
 
 
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc